| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------------------------|-------|------------------------------------------|---------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | A WORLD WITHOUT INFECTIOUS DISEASE | | | | | | | | | | Vir | | | Biotechnology, Inc. | | | | | | | | | 38th January 14, 2020 | | Annual J.P. Morgan Healthcare Conference | | | | | | | | Legal disclaimers Forward-Looking Statements ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-2730369 (State or other juri ...